Two Sigma Advisers’s Avanos Medical AVNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-115,300
| Closed | -$1.29M | – | 212 |
|
|
2025
Q4 | $1.29M | Buy |
115,300
+82,400
| +250% | +$943K | ﹤0.01% | 1354 |
|
|
2025
Q3 | $380K | Sell |
32,900
-1,800
| -5% | -$21.1K | ﹤0.01% | 1887 |
|
|
2025
Q2 | $425K | Sell |
34,700
-16,600
| -32% | -$209K | ﹤0.01% | 1819 |
|
|
2025
Q1 | $735K | Sell |
51,300
-13,100
| -20% | -$205K | ﹤0.01% | 1609 |
|
|
2024
Q4 | $1.03M | Sell |
64,400
-19,900
| -24% | -$394K | ﹤0.01% | 1450 |
|
|
2024
Q3 | $2.03M | Sell |
84,300
-60,100
| -42% | -$1.37M | ﹤0.01% | 1053 |
|
|
2024
Q2 | $2.88M | Buy |
144,400
+8,100
| +6% | +$158K | 0.01% | 1004 |
|
|
2024
Q1 | $2.71M | Sell |
136,300
-4,200
| -3% | -$81.2K | 0.01% | 1062 |
|
|
2023
Q4 | $3.15M | Sell |
140,500
-37,800
| -21% | -$780K | 0.01% | 1050 |
|
|
2023
Q3 | $3.61M | Buy |
178,300
+54,600
| +44% | +$1.24M | 0.01% | 897 |
|
|
2023
Q2 | $3.16M | Sell |
123,700
-19,000
| -13% | -$500K | 0.01% | 968 |
|
|
2023
Q1 | $4.24M | Sell |
142,700
-57,000
| -29% | -$1.65M | 0.01% | 874 |
|
|
2022
Q4 | $5.4M | Sell |
199,700
-39,400
| -16% | -$963K | 0.02% | 753 |
|
|
2022
Q3 | $5.21M | Sell |
239,100
-35,200
| -13% | -$920K | 0.02% | 715 |
|
|
2022
Q2 | $7.5M | Sell |
274,300
-30,400
| -10% | -$873K | 0.02% | 604 |
|
|
2022
Q1 | $10.2M | Buy |
304,700
+7,800
| +3% | +$251K | 0.03% | 514 |
|
|
2021
Q4 | $10.3M | Sell |
296,900
-18,500
| -6% | -$598K | 0.03% | 494 |
|
|
2021
Q3 | $9.84M | Buy |
+315,400
| New | +$10.7M | 0.03% | 526 |
|
|
2019
Q3 | – | Sell |
-15,100
| Closed | -$659K | – | 2223 |
|
|
2019
Q2 | $659K | Sell |
15,100
-44,000
| -74% | -$1.88M | ﹤0.01% | 1699 |
|
|
2019
Q1 | $2.52M | Sell |
59,100
-16,600
| -22% | -$743K | 0.01% | 1120 |
|
|
2018
Q4 | $3.39M | Sell |
75,700
-4,317
| -5% | -$226K | 0.01% | 947 |
|
|
2018
Q3 | $5.48M | Sell |
80,017
-11,600
| -13% | -$747K | 0.01% | 791 |
|
|
2018
Q2 | $5.25M | Buy |
91,617
+11,600
| +14% | +$613K | 0.01% | 830 |
|
|
2018
Q1 | $3.69M | Buy |
80,017
+15,800
| +25% | +$750K | 0.01% | 971 |
|
|
2017
Q4 | $2.97M | Hold |
64,217
| – | – | 0.01% | 1064 |
|
|
2017
Q3 | $2.89M | Buy |
64,217
+28,800
| +81% | +$1.23M | 0.01% | 1034 |
|
|
2017
Q2 | $1.39M | Buy |
35,417
+18,700
| +112% | +$707K | ﹤0.01% | 1374 |
|
|
2017
Q1 | $637K | Sell |
16,717
-31,559
| -65% | -$1.23M | ﹤0.01% | 1789 |
|
|
2016
Q4 | $1.78M | Buy |
48,276
+23,076
| +92% | +$825K | 0.01% | 1243 |
|
|
2016
Q3 | $873K | Buy |
+25,200
| New | +$883K | ﹤0.01% | 1419 |
|
|
2015
Q3 | – | Sell |
-35,000
| Closed | -$1.42M | – | 1802 |
|
|
2015
Q2 | $1.42M | Buy |
+35,000
| New | +$1.57M | 0.01% | 954 |
|
Other funds holding AVNS
AC
VCM
VPM
Two Sigma Advisers's AVNS Position: Q1 2026 in Review
Two Sigma Advisers sold out of Avanos Medical (AVNS) in Q1 2026, closing a stake of 115,300 shares — an estimated $1.29M sold.
Two Sigma Advisers first reported a position in AVNS in Q2 2015 and held it in 31 quarters. The position peaked at $10.3M in Q4 2021. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.
- Two Sigma Advisers reported no remaining Avanos Medical position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 115,300 Avanos Medical shares in Q1 2026, an estimated $1.29M.
- Two Sigma Advisers first reported a position in Avanos Medical in Q2 2015 and held it in 31 quarters.
- Two Sigma Advisers's Avanos Medical position peaked at $10.3M in Q4 2021.
- 257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.